<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8">
    <title></title>
    <link rel="stylesheet" href="/allregs/css/uswds.min.css">
    <link rel="stylesheet" href="/allregs/css/style.css">
  </head>
  <body>

    <header>
        <h2 class="title">
            <a href="/allregs/index.html">Code of Federal Regulations (alpha)</a>
        </h2>
    </header>

    <div class="usa-grid">
      <div class="usa-width-one-whole">
          <h3>
                                <a href="/allregs/index.html">CFR</a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/titles/title21.html">
                                    Title 21
                                </a><span>&nbsp/&nbsp</span>
                                <a href="/allregs/html/parts/21CFR529.html">Part 529
                                </a><span>&nbsp/&nbsp<span>
                                Sec. 529.400  Chlorhexidine tablets and suspension.
                            </h3>
                            <p class="depth1"><em>(a)</em> Specification. Each tablet and each 28-milliliter syringe of suspension contain 1 gram of chlorhexidine dihydrochloride.\1\---------------------------------------------------------------------------</p><p class="depth2">\1\ These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by Sec. 514.111 of this chapter, but may require bioequivalency and safety information.---------------------------------------------------------------------------</p><p class="depth1"><em>(b)</em> Sponsor. See No. 054771 in Sec. 510.600(c) of this chapter.</p><p class="depth1"><em>(c)</em> Conditions of use--(1) Amount. Place 1 or 2 tablets deep in each uterine horn; or infuse a solution of 1 tablet disolved in an appropriate amount of clean boiled water; or infuse one syringe of suspension into the uterus.</p><p class="depth2"><em>(1)</em> Amount. Place 1 or 2 tablets deep in each uterine horn; or infuse a solution of 1 tablet disolved in an appropriate amount of clean boiled water; or infuse one syringe of suspension into the uterus.</p><p class="depth2"><em>(2)</em> Indications for use. For prevention or treatment of metritis and vaginitis in cows and mares when caused by pathogens sensitive to chlorhexidine dihydrochloride.</p><p class="depth2"><em>(3)</em> Limitations. Prior to administration, remove any unattached placental membranes, any excess uterine fluid or debris, and carefully clean external

genitalia. Use a clean, sterile inseminating pipette for administrating solutions and suspensions. Treatment may be repeated in 48 to 72 hours.
[43 FR 10705, Feb. 23, 1979, as amended at 79 FR 10973, Feb. 27, 2014]</p><p class="depth3">Editorial Note: At 79 FR 10973, Feb. 27, 2014, Sec. 529.400 was amended to revising the section heading, however, the section heading was not provided, therefore, the amendment could not be incorporated because of an inaccurate amendatory instruction.</p>
      </div>
    </div>

    <footer class="usa-footer usa-footer-slim" role="contentinfo">
    <div class="usa-grid usa-footer-return-to-top">
      <a href="#">Return to top</a>
    </div>
    <div class="usa-footer-primary-section">
      <div class="usa-grid-full">
        <h5>Built with ‚ù§.
          Code available <a href="https://github.com/anthonygarvan/allregs">on Github.
        </a></h5>
        <h5>All regulations are from the 2015 Annual Edition.
          This is a technical demonstration not intended for serious use.</h5
      </div>
    </div>
  </footer>
  </body>
</html>
